Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460)
:0460
Want to see HK:0460 full AI Analyst Report?
Top Page
Sihuan Pharmaceutical Holdings Group
(0460)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$1.00
▼(-24.24% Downside)
Action:Reiterated
Date:05/01/26
The score is held back primarily by weak cash-flow quality (negative operating and deeply negative free cash flow in 2025 despite reported profits) and a bearish technical setup (price below key moving averages and negative MACD). Offsetting factors include the 2025 earnings rebound and a manageable leverage profile, but valuation remains less supportive given the high P/E and low dividend yield.
Positive Factors
Revenue rebound
A 21.6% revenue rebound and return to positive net income indicate renewed commercial traction in core therapeutic areas. Durable revenue growth over several quarters supports reinvestment in R&D and sales coverage, strengthening medium-term market position and product momentum.
Negative Factors
Weak cash generation
Negative operating and free cash flow amid reported profits signals quality-of-earnings concerns and potential working-capital stress. Persistently weak cash generation can constrain investment, force external financing, and reduce resilience to regulatory or market shocks over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
A 21.6% revenue rebound and return to positive net income indicate renewed commercial traction in core therapeutic areas. Durable revenue growth over several quarters supports reinvestment in R&D and sales coverage, strengthening medium-term market position and product momentum.
Read all positive factors
Sihuan Pharmaceutical Holdings Group (0460) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$9.98B
Dividend Yield0.87%
Average Volume (3M)37.54M
Price to Earnings (P/E)34.2
Beta (1Y)1.02
Revenue Growth37.90%
EPS GrowthN/A
CountryHK
Employees2,667
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding9,329,999,000
10 Day Avg. Volume24,963,024
30 Day Avg. Volume37,542,935
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.72
Price to Sales (P/S)3.85
P/FCF Ratio-46.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2.00Price Target Upside51.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$3.59B
Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model
Company Description
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, meta...
How the Company Makes Money
Sihuan Pharmaceutical primarily makes money by selling pharmaceutical products in China. Its core revenue stream is revenue from drug sales, generated by manufacturing (or sourcing, where applicable) finished pharmaceutical products and distributi...
Sihuan Pharmaceutical Holdings Group Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.62B | 1.90B | 1.86B | 2.18B | 3.04B |
| Gross Profit | 1.80B | 1.24B | 1.30B | 1.49B | 2.43B |
| EBITDA | 642.61M | -208.66M | 334.31M | -1.54B | 931.69M |
| Net Income | 179.70M | -216.66M | -54.02M | -1.91B | 416.51M |
Balance Sheet | |||||
| Total Assets | 11.64B | 10.53B | 11.54B | 12.14B | 14.50B |
| Cash, Cash Equivalents and Short-Term Investments | 4.10B | 3.63B | 4.48B | 4.79B | 5.79B |
| Total Debt | 912.57M | 942.76M | 1.26B | 1.29B | 1.08B |
| Total Liabilities | 4.73B | 5.58B | 6.40B | 6.50B | 5.35B |
| Stockholders Equity | 5.85B | 4.37B | 4.43B | 4.74B | 8.28B |
Cash Flow | |||||
| Free Cash Flow | -218.06M | 57.51M | -95.93M | -355.97M | 64.28M |
| Operating Cash Flow | -23.56M | 243.89M | 199.49M | 46.49M | 665.29M |
| Investing Cash Flow | -296.48M | 758.24M | 169.88M | -1.66B | -337.57M |
| Financing Cash Flow | 358.16M | -1.26B | -419.56M | -238.93M | 750.66M |
Sihuan Pharmaceutical Holdings Group Technical Analysis
Negative
1.32
Price Trends
1.33
Negative
1.38
Negative
1.43
Negative
Market Momentum
-0.07
Positive
34.45
Neutral
23.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0460, the sentiment is Negative. The current price of 1.32 is above the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.33, and below the 200-day MA of 1.43, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 34.45 is Neutral, neither overbought nor oversold. The STOCH value of 23.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0460.
Sihuan Pharmaceutical Holdings Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$29.05B | 9.36 | 13.95% | 4.09% | 1.48% | -1.55% | |
63 Neutral | HK$27.66B | 13.02 | 8.60% | 2.26% | 10.00% | -7.54% | |
58 Neutral | HK$68.48B | 13.21 | 7.19% | 1.69% | 1.52% | 22.54% | |
58 Neutral | HK$30.16B | 3.24 | 7.98% | 2.95% | 4.66% | 20.76% | |
56 Neutral | HK$39.39B | 3.39 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$9.98B | 34.17 | 3.49% | 0.87% | 37.90% | ― |
* Healthcare Sector Average
HK:0460
Sihuan Pharmaceutical Holdings Group
1.08
0.25
29.50%
HK:0867
China Medical System Holdings
11.15
2.57
29.91%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.07
-0.66
-3.93%
HK:1513
Livzon Pharmaceutical Group
27.66
1.46
5.56%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.66
3.46
24.35%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.80
-0.18
-3.67%
Sihuan Pharmaceutical Holdings Group Corporate Events
Sihuan Pharmaceutical Launches Share Buyback as Medical Aesthetics Surge Drives Return to Profit
May 18, 2026
Sihuan Pharmaceutical Holdings Group has announced a share repurchase under its general mandate, buying 10 million shares on the market at an average price of HK$1.0685 and holding them as treasury shares for potential future sale or transfer. The...
Sihuan Pharma Launches Share Buyback as Medical Aesthetics Surges
May 13, 2026
Sihuan Pharmaceutical Holdings Group has strengthened its position as a fast-growing medical aesthetics and biopharmaceutical player, with medical aesthetics now its largest revenue pillar and a key focus of its dual-engine development strategy. T...
Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong
May 12, 2026
Sihuan Pharmaceutical announced that its non-wholly-owned subsidiary Xuanzhu Biopharm has completed the full circulation of its H shares, converting 357,245,794 previously unlisted shares into H shares. Following the conversion, Xuanzhu’s en...
Sihuan Pharma Uses Share Award Buy to Back Profitable Growth in Aesthetics and Biopharma
Apr 21, 2026
Sihuan Pharmaceutical has reported that its medical aesthetics and biopharmaceutical businesses form the core of its growth strategy, underpinned by proprietary RD, a full-spectrum production platform and expanding global reach. The company aims t...
Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial
Apr 20, 2026
Sihuan Pharmaceutical announced that preliminary data from the Phase 1b FORTRESS trial of NG-350A in patients with mismatch repair-proficient locally advanced rectal cancer were presented at the 2026 AACR meeting. NG-350A, combined with standard c...
Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib
Apr 20, 2026
Sihuan Pharmaceutical’s non-wholly-owned subsidiary Xuanzhu Biopharm has reported Phase III data for its next-generation ALK inhibitor dirozalkib (Xuan Fei Ning) in first-line treatment of ALK-positive advanced non-small cell lung cancer in ...
Sihuan Subsidiary Xuanzhu Wins HKEX Approval for H-Share Full Circulation
Apr 17, 2026
Sihuan Pharmaceutical Holdings Group announced that its non-wholly-owned subsidiary, Xuanzhu Biopharmaceutical, has received approval from the Hong Kong Stock Exchange for the listing and dealing of 357,245,794 H shares converted from previously u...
Sihuan Unit Wins China Nod for Phase III Anaprazole Trial in H. pylori
Apr 15, 2026
Sihuan Pharmaceutical’s subsidiary Xuanzhu Biopharm has received approval from China’s drug regulator to launch a Phase III trial of a bismuth-containing quadruple regimen using Anaprazole Sodium Enteric-coated Tablets for Helicobacter...
Sihuan Subsidiary Xuanzhu Biopharm Clears CSRC Filing for Major H-Share Conversion
Apr 12, 2026
Sihuan Pharmaceutical Holdings Group announced that its non-wholly-owned subsidiary Xuanzhu Biopharm has received notification from the CSRC confirming completion of filing for the conversion of 357,245,794 unlisted shares into the same number of ...
Sihuan’s Xuanzhu Biopharm Licenses Two Oncology Drugs to Boston Oncology for MENA Markets
Apr 9, 2026
Xuanzhu Biopharmaceutical, a subsidiary of Sihuan Pharmaceutical Holdings Group, has signed a licensing and supply agreement with Boston Oncology covering its breast cancer drug Bireociclib and lung cancer drug Dirozalkib in 21 Middle East and Nor...
Sihuan Pharma Teams With Biocytogen on AI-Driven Obesity Drug R&D
Apr 1, 2026
Sihuan Pharmaceutical Holdings Group has entered a strategic collaboration with Biocytogen Pharmaceuticals to accelerate development of innovative drugs, initially focusing on next-generation weight loss therapies. The partnership combines Sihuan&...
Sihuan Pharmaceutical’s Medical Aesthetics Push Lifts 2025 Revenue and Margins
Mar 31, 2026
Sihuan Pharmaceutical reported a sharp rebound in 2025, with total revenue rising 37.7% year on year to RMB2.62 billion and group gross profit climbing 45.1% to RMB1.80 billion, lifting gross margin to 68.8%. The performance marks a shift in the c...
Sihuan Pharmaceutical Declares Final Cash Dividend for 2025
Mar 31, 2026
Sihuan Pharmaceutical Holdings Group has declared a final ordinary cash dividend of RMB 0.0096 per share for the financial year ended 31 December 2025, with shareholders’ approval scheduled for 26 June 2026. The dividend will be paid in Hong...
Sihuan Pharma Subsidiary Xuanzhu Narrows Loss as Revenue Doubles in 2025
Mar 30, 2026
Sihuan Pharmaceutical Holdings Group has disclosed the 2025 annual results of its non-wholly owned subsidiary Xuanzhu Biopharmaceutical, which is also listed in Hong Kong. The move informs shareholders and investors about the financial performance...
Sihuan’s Bireociclib Delivers Strong Phase 3 Breast Cancer Data Published in JAMA Oncology
Mar 24, 2026
Sihuan Pharmaceutical announced that the final results of the Phase 3 BRIGHT-2 trial of its novel CDK2/4/6 inhibitor Bireociclib combined with Fulvestrant in HR+/HER2- advanced breast cancer have been published in leading journal JAMA Oncology. Th...
Sihuan Unit Completes Phase III Enrollment for Novel Reflux Esophagitis Drug in China
Mar 22, 2026
Sihuan Pharmaceutical announced that Xuanzhu Biopharm has completed enrollment of all 500 subjects in a phase III clinical trial in China for Anaprazole Sodium Enteric-coated Tablets, branded An Jiu Wei, in adults with reflux esophagitis. The pivo...
Sihuan Pharmaceutical Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 19, 2026
Sihuan Pharmaceutical Holdings Group Ltd. has announced that its board of directors will convene a meeting on 31 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also consider the pu...
Sihuan Pharma Subsidiary Xuanzhu Biopharm Added to Hong Kong Stock Connect
Mar 8, 2026
Sihuan Pharmaceutical announced that its non-wholly-owned subsidiary, Xuanzhu Biopharmaceutical, has been added to the eligible stock lists of both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective 9 March 20...
Sihuan’s Bireociclib Wins First-Line Breast Cancer Approval, Extending Lead in China
Mar 3, 2026
Sihuan Pharmaceutical said its independently developed CDK2/4/6 inhibitor Bireociclib (Xuanyuening) has received Chinese marketing approval for a third indication, as a first-line treatment when combined with aromatase inhibitors for HR+/HER2- adv...
Sihuan Subsidiary Xuanzhu Biopharm Joins Hang Seng Composite Index, Opening Path to Stock Connect
Feb 22, 2026
Xuanzhu Biopharmaceutical, the innovative drug arm of Sihuan Pharmaceutical, has been added to the Hang Seng Composite Index following the latest quarterly review, effective 9 March 2026. The index covers Hong Kong Main Board companies comprising ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.